FDA advisers recommend accelerated approval of a Sarepta gene therapy
The vote followed a daylong hearing, convened virtually, marked by debate over the company’s clinical trial data and impassioned pleas from the parents of boys with Duchenne, a deadly muscle-wasting disease.